Prostate Cell News Volume 2.25 | Jul 15 2011

NIH-Funded Study Shows Reduction in Death for Men with Intermediate-Grade Prostate Cancer
Short-term hormone therapy given in combination with radiation therapy to men with early-stage prostate cancer increased their chances of living longer compared to treatment with radiation therapy alone, according to a clinical trial supported by the National Cancer Institute. [Press release from the National Institutes of Health (NIH) discussing online prepublication in the New England Journal of Medicine]

Scientists Unlock Further Prostate Cancer Secrets
Scientists have taken a further step to identifying men at a greater risk of prostate cancer with the discovery of seven new variants in the human genome that increase the chances of developing the disease. [Press release from The Institute of Cancer Research discussing online prepublication in Nature Genetics]

LABORATORY RESEARCH

Seven Prostate Cancer Susceptibility Loci Identified by a Multi-Stage Genome-Wide Association Study
Researchers followed up ten new association signals through genotyping in 51,311 samples in 30 studies from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. [Nat Genet]

In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen
In this study, the antitumor activity of prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) was evaluated against a panel of prostate cancer cell lines in vitro and in a novel in vivo model of taxane-refractory human prostate cancer. [Mol Cancer Ther]

Anterior Prostate Epithelial AR Inactivation Modifies Estrogen Receptor Expression and Increases Estrogen Sensitivity
To characterize androgen effects on estrogen sensitivity in the mouse prostate, researchers contrasted models of castration-induced androgen withdrawal in the prostate stromal and epithelial compartments with prostate epithelial androgen receptor (AR) knockout mouse model of selective epithelial AR inactivation. [Am J Physiol Endocrinol Metab]

MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer
The objective of this study was to analyze extent and prognostic significance of MAGE-C2/CT10 protein expression in prostate cancer. [PLoS One]

Biological Significance of Perineural Invasion (PNI) in Prostate Cancer
In order to better understand the biological significance of PNI in prostate cancer, researchers aimed to analyze in situ the expression of molecules involved in tumor growth or nerve trophicity. [Prostate]

Organ Specific Glutathione S-Transferase Pi Expression of the Metastatic Androgen Independent Prostate Cancer Cells in Nude Mice
Researchers found that glutathione S-transferase pi (Gst-pi) expression of prostate cancers is dependent on metastatic site, and Gst-pi has an important role in adapting prostate cancer for growth and metastasis involving an alteration of reactive oxygen species signals. [Prostate]

Regulation of Bombesin-Stimulated Cyclooxygenase-2 Expression in Prostate Cancer Cells
In this study, researchers report that bombesin stimulates cyclooxygenase-2 mRNA and protein expression, and the release of prostaglandin E2 from the gastrin-releasing peptide receptor-positive, androgen-insensitive prostate cancer cell line, PC-3. [BMC Mol Biol]

The Dietary Flavonol Fisetin Enhances the Apoptosis-Inducing Potential of TRAIL in Prostate Cancer Cells
This study was designed to investigate the effect of fisetin on the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis potential in prostate cancer cells. [Int J Oncol]

CLINICAL RESEARCH

Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
Researchers randomly assigned 1979 eligible patients with stage T1b, T1c, T2a, or T2b prostate adenocarcinoma and a prostate-specific antigen level of 20 ng per milliliter or less to radiotherapy alone (992 patients) or radiotherapy with 4 months of total androgen suppression starting 2 months before radiotherapy (radiotherapy plus short-term androgen-deprivation therapy, 987 patients). [N Engl J Med]

Lenalidomide Modulates IL-8 and Anti-Prostate Antibody Levels in Men with Biochemically Recurrent Prostate Cancer
Researchers retrospectively explored changes in immunological parameters in men with biochemically recurrent prostate cancer treated with either 5 or 25 mg of lenalidomide in a randomized phase II trial, and determined whether those changes correlated with disease progression. [Prostate]

23 Patients with Organ Confined Low Risk Prostate Cancer Have Been Treated in Clinical Trials Using the ExAblate® Non-Invasive Prostate Cancer System
InSightec Ltd., announced that 23 patients with organ confined low risk prostate cancer have already been treated with its ExAblate® system in clinical trials, showing promising initial results. [InSightec Ltd., Press Release]

National Institutes of Health State-of-the-Science Conference on the Role of Active Surveillance in the Management of Men with Localized Prostate Cancer (FR Doc No: 2011-17307) [National Institutes of Health, United States]

Submission for OMB Review; Comment Request; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) (NCI) (FR Doc No: 2011-17750) [National Institutes of Health, United States]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Cancer Research Global Summit 
August 16-17, 2011 
London, United Kingdom 

NEW The EMBO Meeting 2011 
September 10-13, 2011 
Vienna, Austria 

NEW Cold Spring Harbor – Cell Death 
October 11-15, 2011 
Cold Spring Harbor, United States 

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Post-doctoral Position – Molecular Biology of Prostate Cancer (Baylor College of Medicine)

Postdoctoral Position – Endocrinology of Prostate Cancer (Baylor College of Medicine)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.